A senior scientist at the U.S. Centers for Disease Control and Prevention has resigned, warning that changes in leadership ...

Verve Therapeutics remains an early-stage biotech, making the rally purely acquisition-driven, not based on fundamentals.

Canaccord downgraded Verve Therapeutics (VERV) to Hold from Buy with a price target of $13, down from $39, after Eli Lilly (LLY) announced a definitive agreement to acquire Verve. Lilly will commence ...

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.

Seth MacFarlane has shared a behind-the-scenes mini-documentary to showcase the making of ‘Lush Life: The Lost Sinatra ...

Maria Crawford selects her best mid-year reads ...